MedTrace Logo

Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)

NCT00850863 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2009-02-25

No results posted yet for this study

Summary

COPD is ranked number 3 by the WHO list of important diseases worldwide and is the only disease with increasing mortality. The pathogenesis of cigarette smoke-induced COPD is obscure, therefore more insight is needed to design effective anti-inflammatory agents. Recently it has become clear that cigarette smoke-induced inflammation is not only present in the lungs but also in the blood, and that this systemic inflammation has important consequences for the clinical expression of COPD. The investigators hypothesize that healthy individuals who are susceptible to cigarette smoking demonstrate a higher and aberrant systemic inflammatory response to cigarette smoke. This susceptibility is caused by heterogeneous factors and is associated with various polymorphic genes that interact with each other and with the environment.

Objective:

* To study systemic inflammation in individuals who are or are not susceptible to develop COPD.
* To characterize the switch to chronicity of the systemic inflmmatory response in COPD
* To determine whether the type and severity of the systemic inflammation contributes to the clinical outcome of COPD
* To compare between subjects who are or are not susceptible to develop COPD in peripheral blood, the corticosteroid responsiveness in vitro, and to unravel underlying mechanisms.
* To study the role of candidate genes that may play a role in the development of fixed airway obstruction, and to identify clues for patient's responsiveness to specific drugs
* To develop new biological and clinical markers for the early diagnosis and monitoring of COPD
* To define possible mediators involved in the early induction of COPD in susceptible smokers, and to define new drug targets

Conditions

Sponsors & Collaborators

  • Academisch Ziekenhuis Maastricht

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Nycomed

    collaborator INDUSTRY

  • Top Institute Pharma

    lead OTHER

Principal Investigators

  • Jan-Willem Lammers, Dr. Prof. MD · UMC Utrecht

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2013-01-31
Completion
2015-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00850863 on ClinicalTrials.gov